Key updates to Section 9 recommendations: Cardiovascular: Recommendations 9.9a and 9.9b now specify GLP-1 RA or dual GIP/GLP-1 RA for patients with type 2 diabetes and symptomatic HFpEF, based on demonstrated benefits in heart failure-related symptoms and event reduction
Timing your medications Theres no specific requirement to take Wegovy and sertraline at different times
Measures such as optimizing the overall layout of TCM standard system, strengthening the supply of TCM standards in key fields, promoting the interactive development of TCM standards and scientific and technological innovation, promoting the internationalization of TCM standards, deepening the reform and innovation of TCM standardization, and consolidating the foundation for the development of TCM standardization are taken to achieve the standardization and internationalization of TCM, so as to integrate with mainstream medicine
This central mechanism positions PT-141 as a neuroendocrine modulator rather than a vascular agent
GLP-1 and GIP-based therapies may be appropriate for individuals with Type 2 diabetes, insulin resistance, or those who are overweight (BMI 2730+) with at least one weight-related condition such as high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease
The body weight, muscle mass, muscle strength, glycolipid metabolism, muscle atrophy markers, myogenic differentiation markers, GLUT4 and SIRT1 were analyzed